Insulin resistance in the liver and...

Insulin resistance in the liver and peripheral tissue and dysfunction of the pancreatic beta solitary abode; squalids are the two processes that follow in type 2 diabetes mellitus. In the management of representation 2 diabetes, the goal is to achieve glycemic direction Unfortunately, the longer patients have representation 2 diabetes, the less likely they will be able to achieve and maintain glycemic goals with monotherapy. The combination of an insulin secretagogue and an insulin sensitizer addresses the one and the other processes. A tablet combining glyburide and metformin provides better glycemic superintend and contains agents that can correct the couple underlying processes.

a certain patients with type 2 diabetes progres to the point where dual therapy does not provide adequate bridle In these patients, the addition of a thiazolidinedione can provide better glycemic reign over Dailey and colleagues evaluated the safety and efficacy of a thiazolidinedione, rosiglitazone, in the combination treatment of pattern 2 diabetes mellitus.

The thought was a randomized, double-blind, placebo-controlled multicenter trial of patients with poorly controll pattern 2 diabetes. Poor glycemic hinder was defined as an A1C on a level between 7.1 and 10 percent In addition, patients had to have a material substance mass index of 23 to 40 kg for m2. The first portion of the consideration was an open-label lead-in to the optimal dosage of combined glyburide/metformin. At the period of that phase, patients were randomized to receive 4 mg of rosiglitazone one time daily or placebo for a 24-week period. If glycemic dominion government was not achieved, the dosage of rosiglitazone was increased to 4 mg twice daily. If the participants make knowned hypoglycemia, the dosage of glyburide/ metformin was reduc according to 2.5/500 mg. The main result measure was the A1C of the same height at the end of the trial period. Other last points included A1C levels of les than 7 percent a fasting plasma grape-sugar level of less than 126 mg through dL (7 mmol per L) and lipid horizontals In addition, investigators recorded and graded any adverse mix with drugs events.

There were 365 patients enlisted in the study. The combination therapy of glyburide/metformin plus rosiglitazone provided patients with a significant reduction in A1C evens (-1 percent) compared with patients receiving glyburide/metformin plus placebo. In addition, a significantly larger portion of patients taking triple active medications had A1C flats of less than 7 percent compared with those in the glyburide/metformin plus placebo collection The patients who received three active medications had a statisically significant reduction of 48 mg by dL (1.25 mmol per L) in fasting progeny glucose levels compared with the glyburide/metformin plus placebo assign places to The most common adverse adventures reported during the study period in the glyburide/metformin and rosiglitazone assemblage included mild to moderate edema, hypoglycemia, and a weight gain of 3 kg (66 lb) At no time during the studious mood did patients need third-party assistance because of a hypoglycemic episode.

The authors decide that in patients with stamp 2 diabetes mellitus who are not achieving glycemic direction with a combination of glyburide/metformin, the addition of rosiglitazone can eventuate in improved control. They add that the triple combination improves patients' chances of attaining A1C on a levels of less than 7 percent which could lead to a delay in the necessity for insulin therapy. This benefit occurr with minimal adverse events

KARL E MILLER, MD

Dailey GE 3d et al. Glycemic sway with glyburide/metformin tablets in combination with rosiglitazone in patients with prototype 2 diabetes: a randomized, double-blind trial. Am J M February 15 2004;116:223-9

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group